POSITIONED TO BEA leader in the development of high quality proprietary therapeutic psychedelic-based treatments.
OUR MISSIONMeaningful Impact
Our Mission is to have a meaningful impact on the lives of patients suffering from mental health conditions by developing high quality proprietary therapeutic psychedelic-based treatments in combination with specialized psychotherapies.
Our Expertise
Clinical StrategyR&D
Completion for formulation prototype and samples for clinical testing focusing on GMP quality drugs tested by qualified clinical researchers
IP StrategyMarket Products
Protect go-to-market products, with a focus on developing fast-acting drug delivery and modified release systems with proprietary formulations.
CreateShareholder Value
Invest in core capabilities and intellectual property to create a sustainable differentiated competitive position and focusing on international sales growth.
Leverage & EstablishRelationships
Relationships with healthcare practitioners, researchers and academic institutions will allow us to help support the international medical community.
Timeline
2020
Q4
2021
Q1
2021
Q2
2021
Q3
2021
Q4
2022
Q1
ABOUT US
Xpira’s goal is to leverage its combined expertise to build a leading life sciences company focused on novel treatments with a special focus on eating disorders.
Xpira Pharmaceuticals Inc. (“Xpira”) is formed by leaders in the North America and Dutch pharmaceutical formulation development, clinical, regulatory, market access, product commercialization, and IP space. Xpira’s network has access to international research scientists and institutions to conduct clinical research.